Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa

被引:301
作者
Molloy, S. F. [1 ]
Kanyama, C. [5 ]
Heyderman, R. S. [2 ,6 ,7 ]
Loyse, A. [1 ]
Kouanfack, C. [9 ,10 ]
Chanda, D. [12 ,13 ]
Mfinanga, S. [16 ]
Temfack, E. [11 ,17 ]
Lakhi, S. [13 ]
Lesikari, S. [16 ]
Chan, A. K. [8 ,19 ]
Stone, N. [1 ,12 ,13 ]
Kalata, N. [6 ,7 ]
Karunaharan, N. [1 ,12 ,13 ]
Gaskell, K. [6 ,7 ]
Peirse, M. [6 ,7 ]
Ellis, J. [6 ,7 ]
Chawinga, C. [5 ]
Lontsi, S. [10 ]
Ndong, J. -G. [10 ]
Bright, P. [8 ,12 ,13 ]
Lupiya, D. [8 ]
Chen, T. [4 ]
Bradley, J. [3 ]
Adams, J. [1 ]
Van der Horst, Charles [5 ,20 ]
van Oosterhout, J. J. [8 ]
Sini, V. [10 ]
Mapoure, Y. N. [11 ]
Mwaba, P. [14 ,15 ]
Bicanic, T. [1 ]
Lalloo, D. G. [4 ]
Wang, D. [4 ]
Hosseinipour, M. C. [5 ,20 ]
Lortholary, O. [17 ,18 ]
Jaffar, S. [4 ]
Harrison, T. S. [1 ,5 ]
机构
[1] St Georges Univ London, Inst Infect & Immun, Ctr Global Hlth, London, England
[2] UCL, London, England
[3] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London, England
[4] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England
[5] Univ North Carolina Project, Kamuzu Cent Hosp, Lilongwe, Malawi
[6] Liverpool Wellcome Trust Clin Res Programm, Liverpool, Merseyside, England
[7] Univ Malawi, Coll Med, Blantyre, Malawi
[8] Zomba Cent Hosp, Dignitas Int, Zomba, Malawi
[9] Univ Dschang, Dschang, Cameroon
[10] Agence Natl Rech Sida, Hop Cent Yaounde Site, Yaounde, Cameroon
[11] Douala Gen Hosp, Douala, Cameroon
[12] Inst Med Res & Training, Lusaka, Zambia
[13] Univ Teaching Hosp, Lusaka, Zambia
[14] Lusaka Apex Med Univ, Dept Internal Med, Lusaka, Zambia
[15] Lusaka Apex Med Univ, Directorate Res & Postgrad Studies, Lusaka, Zambia
[16] Natl Inst Med Res, Muhimbili Med Res Ctr, Dar Es Salaam, Tanzania
[17] Inst Pasteur, Mol Mycol Unit, Paris, France
[18] Paris Descartes Univ, Necker Pasteur Ctr Infect Dis & Trop Med, AP HP, IHU Imagine, Paris, France
[19] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Infect Dis, Toronto, ON, Canada
[20] Univ N Carolina, Chapel Hill, NC USA
基金
美国国家卫生研究院; 英国惠康基金; 英国医学研究理事会;
关键词
HIGH-DOSE FLUCONAZOLE; COURSE AMPHOTERICIN-B; COMBINED COHORT; GLOBAL BURDEN; FLUCYTOSINE; THERAPY; DISEASE; TRIAL;
D O I
10.1056/NEJMoa1710922
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Cryptococcal meningitis accounts for more than 100,000 human immunodeficiency virus (HIV)-related deaths per year. We tested two treatment strategies that could be more sustainable in Africa than the standard of 2 weeks of amphotericin B plus flucytosine and more effective than the widely used fluconazole monotherapy. METHODS We randomly assigned HIV-infected adults with cryptococcal meningitis to receive an oral regimen (fluconazole [1200 mg per day] plus flucytosine [100 mg per kilogram of body weight per day] for 2 weeks), 1 week of amphotericin B (1 mg per kilogram per day), or 2 weeks of amphotericin B (1 mg per kilogram per day). Each patient assigned to receive amphotericin B was also randomly assigned to receive fluconazole or flucytosine as a partner drug. After induction treatment, all the patients received fluconazole consolidation therapy and were followed to 10 weeks. RESULTS A total of 721 patients underwent randomization. Mortality in the oral-regimen, 1-week amphotericin B, and 2-week amphotericin B groups was 18.2% (41 of 225), 21.9% (49 of 224), and 21.4% (49 of 229), respectively, at 2 weeks and was 35.1% (79 of 225), 36.2% (81 of 224), and 39.7% (91 of 229), respectively, at 10 weeks. The upper limit of the one-sided 97.5% confidence interval for the difference in 2-week mortality was 4.2 percentage points for the oral-regimen group versus the 2-week amphotericin B groups and 8.1 percentage points for the 1-week amphotericin B groups versus the 2-week amphotericin B groups, both of which were below the predefined 10-percentage-point noninferiority margin. As a partner drug with amphotericin B, flucytosine was superior to fluconazole (71 deaths [31.1%] vs. 101 deaths [45.0%]; hazard ratio for death at 10 weeks, 0.62; 95% confidence interval [CI], 0.45 to 0.84; P = 0.002). One week of amphotericin B plus flucytosine was associated with the lowest 10-week mortality (24.2%; 95% CI, 16.2 to 32.1). Side effects, such as severe anemia, were more frequent with 2 weeks than with 1 week of amphotericin B or with the oral regimen. CONCLUSIONS One week of amphotericin B plus flucytosine and 2 weeks of fluconazole plus flucytosine were effective as induction therapy for cryptococcal meningitis in resourcelimited settings.
引用
收藏
页码:1004 / 1017
页数:14
相关论文
共 29 条
[1]   Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis [J].
Beardsley, J. ;
Wolbers, M. ;
Kibengo, F. M. ;
Ggayi, A. -B. M. ;
Kamali, A. ;
Cuc, N. T. K. ;
Binh, T. Q. ;
Chau, N. V. V. ;
Farrar, J. ;
Merson, L. ;
Phuong, L. ;
Thwaites, G. ;
Van Kinh, N. ;
Thuy, P. T. ;
Chierakul, W. ;
Siriboon, S. ;
Thiansukhon, E. ;
Onsanit, S. ;
Supphamongkholchaikul, W. ;
Chan, A. K. ;
Heyderman, R. ;
Mwinjiwa, E. ;
van Oosterhout, J. J. ;
Imran, D. ;
Basri, H. ;
Mayxay, M. ;
Dance, D. ;
Phimmasone, P. ;
Rattanavong, S. ;
Lalloo, D. G. ;
Day, J. N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (06) :542-554
[2]   Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis [J].
Bicanic, Tihana ;
Bottomley, Christian ;
Loyse, Angela ;
Brouwer, Annemarie E. ;
Muzoora, Conrad ;
Taseera, Kabanda ;
Jackson, Arthur ;
Phulusa, Jacob ;
Hosseinipour, Mina C. ;
van der Horst, Charles ;
Limmathurotsakul, Direk ;
White, Nicholas J. ;
Wilson, Douglas ;
Wood, Robin ;
Meintjes, Graeme ;
Harrison, Thomas S. ;
Jarvis, Joseph N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) :7224-7231
[3]   Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients [J].
Bicanic, Tihana ;
Muzoora, Conrad ;
Brouwer, Annemarie E. ;
Meintjes, Graeme ;
Longley, Nicky ;
Taseera, Kabanda ;
Rebe, Kevin ;
Loyse, Angela ;
Jarvis, Joseph ;
Bekker, Linda-Gail ;
Wood, Robin ;
Limmathurotsakul, Direk ;
Chierakul, Wirongrong ;
Stepniewska, Kasia ;
White, Nicholas J. ;
Jaffar, Shabbar ;
Harrison, Thomas S. .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) :702-709
[4]   Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial [J].
Brouwer, AE ;
Rajanuwong, A ;
Chierakul, W ;
Griffin, GE ;
Larsen, RA ;
White, NJ ;
Harrison, TS .
LANCET, 2004, 363 (9423) :1764-1767
[5]  
Day JN, 2013, NEW ENGL J MED, V368, P2522, DOI [10.1056/NEJMoa1110404, 10.1056/NEJMc1305981]
[6]   Cost-Effective Diagnostic Checklists for Meningitis in Resource-Limited Settings [J].
Durski, Kara N. ;
Kuntz, Karen M. ;
Yasukawa, Kosuke ;
Virnig, Beth A. ;
Meya, David B. ;
Boulware, David R. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (03) :E101-E108
[7]   A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi [J].
Gaskell, Katherine M. ;
Rothe, Camilla ;
Gnanadurai, Roshina ;
Goodson, Patrick ;
Jassi, Chikondi ;
Heyderman, Robert S. ;
Allain, Theresa J. ;
Harrison, Thomas S. ;
Lalloo, David G. ;
Sloan, Derek J. ;
Feasey, Nicholas A. .
PLOS ONE, 2014, 9 (11)
[8]   One-Step Continuous Flow Synthesis of Antifungal WHO Essential Medicine Flucytosine Using Fluorine [J].
Harsanyi, Antal ;
Conte, Annelyse ;
Pichon, Laurent ;
Rabion, Alain ;
Grenier, Sandrine ;
Sandford, Graham .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2017, 21 (02) :273-276
[9]   A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis [J].
Jackson, Arthur T. ;
Nussbaum, Jesse C. ;
Phulusa, Jacob ;
Namarika, Dan ;
Chikasema, Maria ;
Kanyemba, Creto ;
Jarvis, Joseph N. ;
Jaffar, Shabbar ;
Hosseinipour, Mina C. ;
van der Horst, Charles ;
Harrison, Thomas S. .
AIDS, 2012, 26 (11) :1363-1370
[10]  
Jarvis J. N., 2017, C RETR OPP INF SEATT